Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) - Analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Atea Pharmaceuticals in a note issued to investors on Friday, March 7th. William Blair analyst A. Hsieh expects that the company will post earnings per share of ($0.40) for the quarter. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Atea Pharmaceuticals' current full-year earnings is ($2.01) per share. William Blair also issued estimates for Atea Pharmaceuticals' Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.59) EPS and FY2027 earnings at ($1.60) EPS.
Atea Pharmaceuticals Trading Down 0.8 %
AVIR traded down $0.03 during trading hours on Monday, hitting $3.08. The company's stock had a trading volume of 153,335 shares, compared to its average volume of 281,367. The stock has a market cap of $259.72 million, a price-to-earnings ratio of -1.48 and a beta of 0.18. The business's 50-day moving average price is $3.13 and its 200-day moving average price is $3.33. Atea Pharmaceuticals has a 12 month low of $2.75 and a 12 month high of $4.15.
Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.05).
Institutional Trading of Atea Pharmaceuticals
Several hedge funds have recently made changes to their positions in the business. Intech Investment Management LLC bought a new stake in Atea Pharmaceuticals during the third quarter worth approximately $36,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Atea Pharmaceuticals during the 3rd quarter valued at approximately $37,000. Graham Capital Management L.P. purchased a new stake in Atea Pharmaceuticals during the 4th quarter valued at $42,000. Millennium Management LLC bought a new stake in Atea Pharmaceuticals in the fourth quarter worth $75,000. Finally, Zacks Investment Management purchased a new position in Atea Pharmaceuticals during the third quarter worth $80,000. 86.67% of the stock is currently owned by hedge funds and other institutional investors.
About Atea Pharmaceuticals
(
Get Free Report)
Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.
See Also
Before you consider Atea Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atea Pharmaceuticals wasn't on the list.
While Atea Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
